Sanofi Collaboration Drives Lexicon Pharma's (LXRX) 4Q Success; Wedbush Raises Price Target to $28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Lexicon Pharma (LXRX) Reports Q4 EPS of $0.76
March 1, 2016 7:11 AM ESTLexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.76, versus ($0.03) reported last year. Revenue for the quarter came in at $127.3 million, versus $21.5 million reported last year.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
... MoreTrading Radar for 3/1: AutoZone (AZO), Dollar Tree (DLTR), Donaldson (DCI), TiVo (TIVO), Veeva (VEEV) Report
February 29, 2016 2:16 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
Ares Commercial Real Estate (NYSE: ACRE) - consensus EPS $0.27
AutoZone (NYSE: AZO) - consensus EPS $7.28
Bank of Nova Scotia (NYSE: BNS) - consensus EPS $1.42
Concert Pharma (Nasdaq: CNCE) - consensus loss $0.05
Del Frisco's (Nasdaq: DFRG) - consensus EPS $0.36
Diana... More
